Treatment of Recurrent Clostridium Difficile Infection: a Systematic Review

Overview

Journal Infection

Date 2013 Jul 11

PMID 23839210

Citations 26

Authors

J C OHoro

K Jindai

B Kunzer

N Safdar

Affiliations

Soon will be listed here.

Abstract

Background: Clostridium difficile infection (CDI) recurs in nearly one-third of patients who develop an initial infection. Recurrent CDI (RCDI) is associated with considerable morbidity, mortality, and cost. Treatment for RCDI has not been not well examined.

Methods: A systematic review.

Results: Sixty-four articles were identified evaluating eight different treatment approaches: metronidazole, vancomycin, fidaxomicin, nitazoxanide, rifampin, immunoglobulins, probiotics, and fecal bacteriotherapy. The meta-analysis found vancomycin to have a similar efficacy to metronidazole, although studies used varying doses and durations of therapy. Fidaxomicin was slightly more efficacious than vancomycin, though the number of studies was small. Good evidence for probiotics was limited. Fecal bacteriotherapy was found to be highly efficacious in a single randomized trial.

Conclusion: Metronidazole and vancomycin have good evidence for use in RCDI but heterogeneity in treatment duration and dose precludes robust conclusions. Fidaxomicin may have a role in treatment, but evidence is limited to subgroup analyses. Fecal bacteriotherapy was the most efficacious. Saccharomyces boulardii may have a role as adjunctive treatment.

Citing Articles

Guidelines for Antibiotics Prescription in Critically Ill Patients.

Khilnani G, Tiwari P, Mittal S, Kulkarni A, Chaudhry D, Zirpe K Indian J Crit Care Med. 2024; 28(Suppl 2):S104-S216.

PMID: 39234229 PMC: 11369928. DOI: 10.5005/jp-journals-10071-24677.

Probiotics for Prevention and Treatment of Clostridium difficile Infection.

Valdes-Varela L, Gueimonde M, Ruas-Madiedo P Adv Exp Med Biol. 2024; 1435:101-116.

PMID: 38175473 DOI: 10.1007/978-3-031-42108-2_6.

Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy.

Shirley D, Tornel W, Warren C, Moonah S Pediatrics. 2023; 152(3).

PMID: 37560802 PMC: 10471512. DOI: 10.1542/peds.2023-062307.

Biochemical Characterizations of the Putative Endolysin Ecd09610 Catalytic Domain from .

Sekiya H, Yamaji H, Yoshida A, Matsunami R, Kamitori S, Tamai E Antibiotics (Basel). 2022; 11(8).

PMID: 36010000 PMC: 9405191. DOI: 10.3390/antibiotics11081131.

Characterization of an Endolysin Targeting That Affects Spore Outgrowth.

Mondal S, Akter A, Draper L, Ross R, Hill C Int J Mol Sci. 2021; 22(11).

PMID: 34073633 PMC: 8199566. DOI: 10.3390/ijms22115690.

References

MacConnachie A, Fox R, Kennedy D, Seaton R . Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM. 2009; 102(11):781-4. DOI: 10.1093/qjmed/hcp118. View

Louie T, Cannon K, Byrne B, Emery J, Ward L, Eyben M . Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012; 55 Suppl 2:S132-42. PMC: 3388020. DOI: 10.1093/cid/cis338. View

Seal D, Borriello S, Barclay F, Welch A, Piper M, Bonnycastle M . Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol. 1987; 6(1):51-3. DOI: 10.1007/BF02097191. View

McDonald L, Killgore G, Thompson A, Owens Jr R, Kazakova S, Sambol S . An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005; 353(23):2433-41. DOI: 10.1056/NEJMoa051590. View

Postigo R, Kim J . Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection. 2012; 40(6):643-8. DOI: 10.1007/s15010-012-0307-9. View

Russell G, Kaplan J, Ferraro M, Michelow I . Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics. 2010; 126(1):e239-42. DOI: 10.1542/peds.2009-3363. View

Leung D, Kelly C, Boguniewicz M, Pothoulakis C, Lamont J, Flores A . Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991; 118(4 Pt 1):633-7. DOI: 10.1016/s0022-3476(05)83393-1. View

Murphy C, Vernon M, Cullen M . Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing. 2005; 35(1):85-6. DOI: 10.1093/ageing/afi212. View

Wilcox M . Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004; 53(5):882-4. DOI: 10.1093/jac/dkh176. View

10.

Elmer G, McFarland L, Surawicz C, Danko L, Greenberg R . Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999; 13(12):1663-8. DOI: 10.1046/j.1365-2036.1999.00666.x. View

11.

Jorup-Ronstrom C, Hakanson A, Sandell S, Edvinsson O, Midtvedt T, Persson A . Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol. 2012; 47(5):548-52. DOI: 10.3109/00365521.2012.672587. View

12.

Baines S, OConnor R, Freeman J, Fawley W, Harmanus C, Mastrantonio P . Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother. 2008; 62(5):1046-52. DOI: 10.1093/jac/dkn313. View

13.

Khoruts A, Dicksved J, Jansson J, Sadowsky M . Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010; 44(5):354-60. DOI: 10.1097/MCG.0b013e3181c87e02. View

14.

DSouza A, Rajkumar C, Cooke J, Bulpitt C . Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002; 324(7350):1361. PMC: 115209. DOI: 10.1136/bmj.324.7350.1361. View

15.

Johnson S, Schriever C, Galang M, Kelly C, Gerding D . Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007; 44(6):846-8. DOI: 10.1086/511870. View

16.

Jorup-Ronstrom C, Hakanson A, Persson A, Midtvedt T, Norin E . [Feces culture successful therapy in Clostridium difficile diarrhea]. Lakartidningen. 2006; 103(46):3603-5. View

17.

Musher D, Logan N, Mehendiratta V, Melgarejo N, Garud S, Hamill R . Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother. 2007; 59(4):705-10. DOI: 10.1093/jac/dkl553. View

18.

Hellemans R, Naegels S, Holvoet J . Fecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality. Acta Gastroenterol Belg. 2009; 72(2):269-70. View

19.

Harkonen N . [Reccurent pseudomembranous colitis treated with the donor feces]. Duodecim. 1996; 112(19):1803-4. View

20.

Yoon S, Brandt L . Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010; 44(8):562-6. DOI: 10.1097/MCG.0b013e3181dac035. View